{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T05:28:40Z","timestamp":1775798920762,"version":"3.50.1"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Clinical trials on the use of COVID-19 convalescent plasma remain inconclusive. While data on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses hint to a dose-response relationship between convalescent plasma neutralizing antibody levels and mortality. In particular, patients with primary and secondary antibody deficiency might benefit from this approach. However, testing of neutralizing antibodies is limited to specialized biosafety level 3 laboratories and is a time- and labor-intense procedure. In this single center study of 206 COVID-19 convalescent patients, clinical data, results of commercially available ELISA testing of SARS-CoV-2 spike-IgG and \u2013IgA, and levels of neutralizing antibodies, determined by plaque reduction neutralization testing (PRNT), were analyzed. At a medium time point of 58 days after symptom onset, only 12.6% of potential plasma donors showed high levels of neutralizing antibodies (PRNT50\u00a0\u2265 1:320). Multivariable proportional odds logistic regression analysis revealed need for hospitalization due to COVID-19 (odds ratio 6.87; <jats:italic>p<\/jats:italic>-value 0.0004) and fever (odds ratio 3.00; <jats:italic>p<\/jats:italic>-value 0.0001) as leading factors affecting levels of SARS-CoV-2 neutralizing antibody titers in convalescent plasma donors. Using penalized estimation, a predictive proportional odds logistic regression model including the most important variables hospitalization, fever, age, sex, and anosmia or dysgeusia was developed. The predictive discrimination for PRNT50 \u2265 1:320 was reasonably good with AUC: 0.86 (with 95% CI: 0.79\u20130.92). Combining clinical and ELISA-based pre-screening, assessment of neutralizing antibodies could be spared in 75% of potential donors with a maximal loss of 10% of true positives (PRNT50 \u2265 1:320).<\/jats:p>","DOI":"10.3389\/fimmu.2020.628971","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T04:52:56Z","timestamp":1611895976000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":58,"title":["Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses"],"prefix":"10.3389","volume":"11","author":[{"given":"Stephan","family":"Schlickeiser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatjana","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Wittke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabeel","family":"Al Besher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Kalus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Pru\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Kurth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Zoller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Witzenrath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leif Erik","family":"Sander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel A.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Scheibenbogen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Dieter","family":"Volk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Drosten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor M.","family":"Corman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leif G.","family":"Hanitsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1172\/jci138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J Clin Invest"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3851\/imp3243","article-title":"Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience","volume":"23","author":"Ko","year":"2018","journal-title":"Antivir Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.06.028","article-title":"Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients","volume":"95","author":"Joyner","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc Natl Acad Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma","volume":"323","author":"Shen","year":"2020","journal-title":"Jama"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.chest.2020.03.039","article-title":"Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection","volume":"158","author":"Zhang","year":"2020","journal-title":"Chest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19","volume":"324","author":"Li","year":"2020","journal-title":"Jama"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.01.20139857","article-title":"Convalescent Plasma for COVID-19. A randomized clinical trial","author":"Gharbharan","year":"2020","journal-title":"medRxiv"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3939","article-title":"Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)","volume":"371","author":"Agarwal","year":"2020","journal-title":"Bmj"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.12.20169359","article-title":"Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience","author":"Joyner","year":"2020","journal-title":"medRxiv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent plasma therapy for B-cell\u2013depleted patients with protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.596761","article-title":"Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19","volume":"11","author":"Damme","year":"2020","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1256","article-title":"Covid-19: FDA approves use of convalescent plasma to treat critically ill patients","volume":"368","author":"Tanne","year":"2020","journal-title":"Bmj"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.02005-20","article-title":"Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients","volume":"58","author":"Luchsinger","year":"2020","journal-title":"J Clin Microbiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0913-5","article-title":"A serological assay to detect SARS-CoV-2 seroconversion in humans","volume":"26","author":"Amanat","year":"2020","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103101","article-title":"Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity","volume":"62","author":"Padoan","year":"2020","journal-title":"Ebiomedicine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3201\/eid2607.200841","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2\u2013Specific Antibody Responses in Coronavirus Disease 2019 Patients - Volume 26, Number 7\u2014July 2020 - Emerging Infectious Diseases journal - CDC","volume":"26","author":"Okba","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa656","article-title":"Independent side-by-side validation and comparison of four serological platforms for SARS-CoV-2 antibody testing","author":"Jahrsd\u00f6rfer","year":"2020","journal-title":"J Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41586-020-2912-6","article-title":"Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City","author":"Stadlbauer","year":"2020","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.06.024","article-title":"Validation of a commercially available SARS-CoV-2 serological immunoassay","volume":"26","author":"Meyer","year":"2020","journal-title":"Clin Microbiol Infec"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2020.114031","article-title":"Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma","volume":"288","author":"von Rhein","year":"2020","journal-title":"J Virol Methods"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1835448","article-title":"Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)","volume":"9","author":"Meyer","year":"2020","journal-title":"Emerg Microbes Infec"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-020-01464-x","article-title":"Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19)","volume":"48","author":"Kurth","year":"2020","journal-title":"Infection"},{"key":"B26","unstructured":""},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"W\u00f6lfel","year":"2020","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.049","article-title":"A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model","volume":"183","author":"Kreye","year":"2020","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression Modeling Strategies, With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis","author":"Harrell","year":"2015"},{"key":"B30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-0-387-77244-8_2","article-title":"Clinical Prediction Models, A Practical Approach to Development, Validation, and Updating","author":"Steyerberg","year":"2008","journal-title":"Stat Biol Heal"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s0167-5877(00)00119-7","article-title":"Conditional dependence between tests affects the diagnosis and surveillance of animal diseases","volume":"45","author":"Gardner","year":"2000","journal-title":"Prev Vet Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007079","article-title":"Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion","volume":"136","author":"Xia","year":"2020","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa505","article-title":"SARS-CoV-2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in COVID-19 Patients","volume":"222","author":"Bradfute","year":"2020","journal-title":"J Infect Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00341-2","article-title":"Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial","volume":"9","author":"Ibrahim","year":"2020","journal-title":"Infect Dis Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1345","article-title":"Sustained responses of neutralizing antibodies against MERS-CoV in recovered patients and their therapeutic applicability","author":"Kim","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1143","article-title":"Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection","author":"Wang","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.14.20151126","article-title":"SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months","author":"Wajnberg","year":"2020","journal-title":"medRxiv"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/trf.16119","article-title":"Characterization of 100 sequential SARS-CoV-2 convalescent plasma donations","author":"Jungbauer","year":"2020","journal-title":"Transfusion"},{"key":"B39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/trf.16101","article-title":"SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with nonsevere disease","volume":"61","author":"Gniadek","year":"2020","journal-title":"Transfusion"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16065","article-title":"Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program","volume":"60","author":"Wendel","year":"2020","journal-title":"Transfusion"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/jci142004","article-title":"Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population","volume":"130","author":"Klein","year":"2020","journal-title":"J Clin Invest"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13185","article-title":"Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial","author":"Madariaga","year":"2020","journal-title":"J Intern Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e1003358","DOI":"10.1371\/journal.pmed.1003358","article-title":"Seroprevalence of SARS-CoV-2 antibodies in people with an acute loss in their sense of smell and\/or taste in a community-based population in London, UK: An observational cohort study","volume":"17","author":"Makaronidis","year":"2020","journal-title":"PloS Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.24.20181206","article-title":"Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany","author":"Aziz","year":"2020","journal-title":"medRxiv"},{"key":"B45","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nrendo.2012.206","article-title":"Gonadal steroids and humoral immunity","volume":"9","author":"Sakiani","year":"2013","journal-title":"Nat Rev Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cellbio-100616-060718","article-title":"Sex and Gender Differences in the Outcomes of Vaccination over the Life Course","volume":"33","author":"Flanagan","year":"2017","journal-title":"Annu Rev Cell Dev Bi"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.08.003","article-title":"Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions","volume":"53","author":"Bunders","year":"2020","journal-title":"Immunity"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2700-3","article-title":"Sex differences in immune responses that underlie COVID-19 disease outcomes","volume":"588","author":"Takahashi","year":"2020","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.584251","article-title":"Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals","volume":"11","author":"Brochot","year":"2020","journal-title":"Front Microbiol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25989","article-title":"A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex","volume":"92","author":"Zeng","year":"2020","journal-title":"J Med Virol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.es.2020.25.47.2001752","article-title":"Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020","volume":"25","author":"Santos-H\u00f6vener","year":"2020","journal-title":"Eurosurveillance"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.06.20207472","article-title":"Clinical, laboratory, and temporal predictors of neutralizing antibodies to SARS-CoV-2 after COVID-19","author":"Boonyaratanakornkit","year":"2020","journal-title":"medRxiv"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1172\/jci141206","article-title":"Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor binding domain IgG correlate with virus neutralization","volume":"130","author":"Salazar","year":"2020","journal-title":"J Clin Invest"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.es.2020.25.45.2001754","article-title":"Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020","volume":"25","author":"Mehew","year":"2020","journal-title":"Eurosurveillance"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.4616","article-title":"Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa721","article-title":"Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients","volume":"71","author":"Wang","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15918","article-title":"Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation","volume":"60","author":"Li","year":"2020","journal-title":"Transfusion"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.12.20230466","article-title":"Sex differences in the decline of neutralizing antibodies to SARS-CoV-2","author":"Grzelak","year":"2020","journal-title":"medRxiv"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.12928832.v1","article-title":"Dataset from Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity","author":"Padoan","year":"2020"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.628971\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T04:53:00Z","timestamp":1611895980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.628971\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2020.628971"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.628971","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]},"article-number":"628971"}}